ReviewBlood2022
EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.
Keri Toner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this paperpooled itcites it
ReviewBlood2022
Keri Toner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.